376 related articles for article (PubMed ID: 22851526)
1. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
Werk M; Langner S; Reinkensmeier B; Boettcher HF; Tepe G; Dietz U; Hosten N; Hamm B; Speck U; Ricke J
Circulation; 2008 Sep; 118(13):1358-65. PubMed ID: 18779447
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison.
Fusaro M; Cassese S; Ndrepepa G; King LA; Tada T; Ott I; Kastrati A
Int J Cardiol; 2013 Oct; 168(4):4002-9. PubMed ID: 23890909
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries.
Kayssi A; Al-Jundi W; Papia G; Kucey DS; Forbes T; Rajan DK; Neville R; Dueck AD
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012510. PubMed ID: 30684445
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs.
Kayssi A; Al-Atassi T; Oreopoulos G; Roche-Nagle G; Tan KT; Rajan DK
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011319. PubMed ID: 27490003
[TBL] [Abstract][Full Text] [Related]
6. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis.
Wu R; Li Z; Wang M; Chang G; Yao C; Wang S
Int J Surg; 2017 Jun; 42():72-82. PubMed ID: 28461145
[TBL] [Abstract][Full Text] [Related]
9. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.
Rittger H; Brachmann J; Sinha AM; Waliszewski M; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Breithardt OA; Schmidt M; Zimmermann S; Lonke S; von Cranach M; Nguyen TV; Daniel WG; Wöhrle J
J Am Coll Cardiol; 2012 Apr; 59(15):1377-82. PubMed ID: 22386286
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
[TBL] [Abstract][Full Text] [Related]
11. Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.
Du X; Wang F; Wu DM; Zhang MH; Jia X; Zhang JW; Zhuang BX; Zhao Y; Guo PF; Bi W; Fu WG; Guo W; Wang SM
Medicine (Baltimore); 2019 Mar; 98(13):e14840. PubMed ID: 30921183
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia.
Liistro F; Porto I; Angioli P; Grotti S; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
Circulation; 2013 Aug; 128(6):615-21. PubMed ID: 23797811
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure.
Kubo S; Kadota K; Otsuru S; Hasegawa D; Habara S; Tada T; Tanaka H; Fuku Y; Katoh H; Goto T; Mitsudo K
EuroIntervention; 2015 Jan; 10(9):e1-8. PubMed ID: 25599699
[TBL] [Abstract][Full Text] [Related]
14. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.
Cassese S; Piccolo R; Galasso G; De Rosa R; Piscione F
Int J Cardiol; 2011 Jul; 150(1):84-9. PubMed ID: 21315461
[TBL] [Abstract][Full Text] [Related]
15. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.
Katsanos K; Spiliopoulos S; Karunanithy N; Krokidis M; Sabharwal T; Taylor P
J Vasc Surg; 2014 Apr; 59(4):1123-1133.e8. PubMed ID: 24661896
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis.
Feng H; Chen X; Guo X; Zhang Z; Zhang Z; Liu B; Lian L
BMC Cardiovasc Disord; 2020 Aug; 20(1):395. PubMed ID: 32867681
[TBL] [Abstract][Full Text] [Related]
17. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials.
Fusaro M; Cassese S; Ndrepepa G; Tepe G; King L; Ott I; Nerad M; Schunkert H; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1284-93. PubMed ID: 24355118
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial.
Teichgräber U; Ingwersen M; Platzer S; Lehmann T; Zeller T; Aschenbach R; Scheinert D
Trials; 2021 Sep; 22(1):665. PubMed ID: 34583746
[TBL] [Abstract][Full Text] [Related]
19. Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH).
Ott I; Cassese S; Groha P; Steppich B; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Hiendlmayer R; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
Circulation; 2017 Jun; 135(23):2218-2226. PubMed ID: 28424222
[TBL] [Abstract][Full Text] [Related]
20. Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial.
Barco S; Sebastian T; Voci D; Engelberger RP; Grigorean A; Holy E; Leeger C; Münger M; Périard D; Probst E; Spescha R; Held U; Kucher N
Trials; 2022 Apr; 23(1):334. PubMed ID: 35449070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
